Impact of Antecedent Aspirin Use on Infarct Size, Bleeding and Composite Endpoint in Patients with de Novo Acute Myocardial Infarction

Asim Enhos, Erdem Karacop Bezmialem Foundation University, Faculty of Medicine, Department of Cardiology, Istanbul, TurkeyCorrespondence: Erdem KaracopBezmialem Foundation University, Faculty of Medicine, Department of Cardiology, Adnan Menderes Avenue, Vatan Street, Fatih, 34093, Istanbul, TurkeyTe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Enhos A, Karacop E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	acute myocardial infarction aspirin infarct size primary prevention Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/da539fe674a14cf691ada06a0d458e51
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:da539fe674a14cf691ada06a0d458e51
record_format	dspace
spelling	oai:doaj.org-article:da539fe674a14cf691ada06a0d458e512021-12-02T15:52:56ZImpact of Antecedent Aspirin Use on Infarct Size, Bleeding and Composite Endpoint in Patients with de Novo Acute Myocardial Infarction1178-203Xhttps://doaj.org/article/da539fe674a14cf691ada06a0d458e512021-05-01T00:00:00Zhttps://www.dovepress.com/impact-of-antecedent-aspirin-use-on-infarct-size-bleeding-and-composit-peer-reviewed-fulltext-article-TCRMhttps://doaj.org/toc/1178-203XAsim Enhos, Erdem Karacop Bezmialem Foundation University, Faculty of Medicine, Department of Cardiology, Istanbul, TurkeyCorrespondence: Erdem KaracopBezmialem Foundation University, Faculty of Medicine, Department of Cardiology, Adnan Menderes Avenue, Vatan Street, Fatih, 34093, Istanbul, TurkeyTel +90 212 453 17 00Fax +90 212 621 75 80Email erdemkaracop@hotmail.comBackground: The study aimed to evaluate the impact of antecedent aspirin use on infarct size, bleeding and composite endpoint in patients with de novo acute myocardial infarction.Patients and Methods: A total of 562 consecutive patients with de novo acute myocardial infarction were included in this prospective cohort study. Patients were assigned into two groups based on presence (n=212) and absence (n=350) of prior aspirin use. Primary endpoint was myocardial infarct size, as estimated by troponin I peak. In-hospital mortality, bleeding and composite clinical endpoint including cardiogenic shock, stroke, in-hospital mortality and major bleeding were also evaluated.Results: Although GRACE and CRUSADE scores were higher, troponin I peak was lower in prior aspirin users. This result was maintained after adjustment for baseline ischemic risk profile and other major confounders including MI type and location. Despite high CRUSADE score, there was no increase in major and minor bleeding. Minimal bleeding was higher in antecedent aspirin users. When it was adjusted for the CRUSADE score, a similar risk was reported.Conclusion: Patients with de novo acute myocardial infarction using aspirin for primary prevention have an unexpectedly smaller infarct size and similar bleeding rates.Keywords: acute myocardial infarction, aspirin, infarct size, primary preventionEnhos AKaracop EDove Medical Pressarticleacute myocardial infarctionaspirininfarct sizeprimary preventionTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 441-452 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	acute myocardial infarction aspirin infarct size primary prevention Therapeutics. Pharmacology RM1-950
spellingShingle	acute myocardial infarction aspirin infarct size primary prevention Therapeutics. Pharmacology RM1-950 Enhos A Karacop E Impact of Antecedent Aspirin Use on Infarct Size, Bleeding and Composite Endpoint in Patients with de Novo Acute Myocardial Infarction
description	Asim Enhos, Erdem Karacop Bezmialem Foundation University, Faculty of Medicine, Department of Cardiology, Istanbul, TurkeyCorrespondence: Erdem KaracopBezmialem Foundation University, Faculty of Medicine, Department of Cardiology, Adnan Menderes Avenue, Vatan Street, Fatih, 34093, Istanbul, TurkeyTel +90 212 453 17 00Fax +90 212 621 75 80Email erdemkaracop@hotmail.comBackground: The study aimed to evaluate the impact of antecedent aspirin use on infarct size, bleeding and composite endpoint in patients with de novo acute myocardial infarction.Patients and Methods: A total of 562 consecutive patients with de novo acute myocardial infarction were included in this prospective cohort study. Patients were assigned into two groups based on presence (n=212) and absence (n=350) of prior aspirin use. Primary endpoint was myocardial infarct size, as estimated by troponin I peak. In-hospital mortality, bleeding and composite clinical endpoint including cardiogenic shock, stroke, in-hospital mortality and major bleeding were also evaluated.Results: Although GRACE and CRUSADE scores were higher, troponin I peak was lower in prior aspirin users. This result was maintained after adjustment for baseline ischemic risk profile and other major confounders including MI type and location. Despite high CRUSADE score, there was no increase in major and minor bleeding. Minimal bleeding was higher in antecedent aspirin users. When it was adjusted for the CRUSADE score, a similar risk was reported.Conclusion: Patients with de novo acute myocardial infarction using aspirin for primary prevention have an unexpectedly smaller infarct size and similar bleeding rates.Keywords: acute myocardial infarction, aspirin, infarct size, primary prevention
format	article
author	Enhos A Karacop E
author_facet	Enhos A Karacop E
author_sort	Enhos A
title	Impact of Antecedent Aspirin Use on Infarct Size, Bleeding and Composite Endpoint in Patients with de Novo Acute Myocardial Infarction
title_short	Impact of Antecedent Aspirin Use on Infarct Size, Bleeding and Composite Endpoint in Patients with de Novo Acute Myocardial Infarction
title_full	Impact of Antecedent Aspirin Use on Infarct Size, Bleeding and Composite Endpoint in Patients with de Novo Acute Myocardial Infarction
title_fullStr	Impact of Antecedent Aspirin Use on Infarct Size, Bleeding and Composite Endpoint in Patients with de Novo Acute Myocardial Infarction
title_full_unstemmed	Impact of Antecedent Aspirin Use on Infarct Size, Bleeding and Composite Endpoint in Patients with de Novo Acute Myocardial Infarction
title_sort	impact of antecedent aspirin use on infarct size, bleeding and composite endpoint in patients with de novo acute myocardial infarction
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/da539fe674a14cf691ada06a0d458e51
work_keys_str_mv	AT enhosa impactofantecedentaspirinuseoninfarctsizebleedingandcompositeendpointinpatientswithdenovoacutemyocardialinfarction AT karacope impactofantecedentaspirinuseoninfarctsizebleedingandcompositeendpointinpatientswithdenovoacutemyocardialinfarction
_version_	1718385601703575552

Impact of Antecedent Aspirin Use on Infarct Size, Bleeding and Composite Endpoint in Patients with de Novo Acute Myocardial Infarction

Ejemplares similares